SNGX
Soligenix, Inc.
Price Chart
Latest Quote
$0.40
-0.00 (-0.62%)
Current Price
| Previous Close | $0.40 |
| Open | $0.40 |
| Day High | $0.41 |
| Day Low | $0.40 |
| Volume | 840,833 |
Stock Information
| Shares Outstanding | 14.82M |
| Total Debt | $331K |
| Cash Equivalents | $6.03M |
| Net Income | $-10.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.92M |
| EPS (TTM) | $-1.45 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $607K |
| Income | $-10.95M |
| Book/sh | $0.29 |
| Cash/sh | $0.41 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 1.67 |
| Current Ratio | 1.81 |
| Debt/Eq | 10.70 |
Returns & Margins
| ROA | -99.73% |
| ROE | -326.87% |
Ownership
| Insider Ownership | 0.11% |
| Institutional Ownership | 5.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.60 |
| P/B | 1.36 |
Analyst Data
| Recommendation | none |
| Target Price | $1.75 |
Technical Indicators
| SMA20 | $0.54 |
| SMA50 | $0.66 |
| SMA200 | $1.28 |
| RSI | 9.52 |
| ATR | 0.0650 |
| Shares Float | 14.04M |
| Short Float | 43.99% |
| Short Ratio | 0.36 |
| Volatility | 1.84 |
| Rel Volume | 0.04 |
Performance History
| Week | -6.98% |
| Month | +5.26% |
| Quarter | -67.21% |
| 6 Months | -73.68% |
| YTD | -71.83% |
| Year | -77.78% |
| 3 Years | -96.58% |
| 5 Years | -99.86% |
| 10 Years | -99.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.40 | 898,700 |
| 2026-06-17 | $0.40 | 716,200 |
| 2026-06-16 | $0.43 | 795,600 |
| 2026-06-15 | $0.45 | 1,119,100 |
| 2026-06-12 | $0.43 | 813,300 |
| 2026-06-11 | $0.43 | 760,200 |
| 2026-06-10 | $0.46 | 1,405,100 |
| 2026-06-09 | $0.43 | 1,485,500 |
| 2026-06-08 | $0.42 | 13,791,000 |
| 2026-06-05 | $0.44 | 1,479,500 |
| 2026-06-04 | $0.48 | 2,745,100 |
| 2026-06-03 | $0.48 | 6,771,700 |
| 2026-06-02 | $0.75 | 4,734,000 |
| 2026-06-01 | $0.83 | 5,673,800 |
| 2026-05-29 | $0.91 | 13,165,700 |
| 2026-05-28 | $0.97 | 21,990,900 |
| 2026-05-27 | $0.87 | 246,553,800 |
| 2026-05-26 | $0.51 | 93,814,000 |
| 2026-05-22 | $0.39 | 937,200 |
| 2026-05-21 | $0.39 | 742,700 |
| 2026-05-20 | $0.39 | 398,500 |
| 2026-05-19 | $0.38 | 830,000 |
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
đ° Latest News
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month â Ebola Vaccine Optimism Fuels Retail Frenzy
Stocktwits âĸ 2026-05-27T11:28:01Z
SNGX Phase 3 Trial Halted on HyBryte
InvestorsHub âĸ 2026-04-28T15:06:46Z
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky
Simply Wall St. âĸ 2025-08-20T10:24:19Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-08-18T14:30:20ZSoligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Benzinga âĸ 2025-07-31T13:00:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $119,371 | $742,048 | $550,822 |
| Cost Of Revenue | $0 | $119,371 | $742,048 | $550,822 |
| Total Revenue | $0 | $0 | $0 | $250,000 |
| Operating Revenue | $0 | $0 | $0 | $250,000 |
| Expenses | ||||
| Total Expenses | $11,845,476 | $9,464,985 | $7,674,156 | $14,356,035 |
| Other Income Expense | $-11,689 | $575,320 | $-185,248 | $-24,628 |
| Other Non Operating Income Expenses | $125 | $43 | $43,223 | $5,921 |
| Net Non Operating Interest Income Expense | $270,170 | $213,975 | $-49,129 | $-822,611 |
| Total Other Finance Cost | $-270,170 | $-213,975 | $49,129 | - |
| Operating Expense | $11,845,476 | $9,345,614 | $6,932,108 | $13,805,213 |
| General And Administrative Expense | $4,359,663 | $4,215,908 | $4,482,552 | $6,692,904 |
| Interest Expense | - | $-213,975 | $49,129 | $822,611 |
| Interest Expense Non Operating | - | $-213,975 | $49,129 | $822,611 |
| Other Operating Expenses | - | $-93,883 | $-863,143 | $-831,780 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Net Interest Income | $270,170 | $213,975 | $-49,129 | $-822,611 |
| Normalized Income | $-11,069,086 | $-8,814,815 | $-5,963,437 | $-13,770,142 |
| Net Income From Continuing And Discontinued Operation | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Total Operating Income As Reported | $-11,845,476 | $-9,439,497 | $-7,697,940 | $-14,238,904 |
| Net Income Common Stockholders | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Net Income | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Net Income Including Noncontrolling Interests | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Net Income Continuous Operations | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Pretax Income | $-11,586,995 | $-8,675,690 | $-7,908,533 | $-14,953,274 |
| Special Income Charges | $0 | $312,753 | $-273,020 | $0 |
| Operating Income | $-11,845,476 | $-9,464,985 | $-7,674,156 | $-14,106,035 |
| Gross Profit | $0 | $-119,371 | $-742,048 | $-300,822 |
| Per Share | ||||
| Diluted EPS | $-2.14 | $-4.98 | $-12.66 | $-76.96 |
| Basic EPS | $-2.14 | $-4.98 | $-12.66 | $-76.96 |
| Other | ||||
| Tax Effect Of Unusual Items | $-520 | $27,038 | $-51,178 | $-2,352 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,830,438 | $-10,034,448 | $-7,439,131 | $-14,075,552 |
| Total Unusual Items | $-11,814 | $575,277 | $-228,471 | $-30,549 |
| Total Unusual Items Excluding Goodwill | $-11,814 | $575,277 | $-228,471 | $-30,549 |
| Reconciled Depreciation | $3,224 | $5,814 | $6,554 | $24,562 |
| EBITDA (Bullshit earnings) | $-11,842,252 | $-9,459,171 | $-7,667,602 | $-14,106,101 |
| EBIT | $-11,845,476 | $-9,464,985 | $-7,674,156 | $-14,130,663 |
| Diluted Average Shares | $5,188,799 | $1,660,413 | $484,995 | $179,459 |
| Basic Average Shares | $5,188,799 | $1,660,413 | $484,995 | $179,459 |
| Diluted NI Availto Com Stockholders | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Tax Provision | $-506,615 | $-409,114 | $-1,767,803 | $-1,154,935 |
| Gain On Sale Of Security | $-11,814 | $262,524 | $44,549 | $-30,549 |
| Research And Development | $7,485,813 | $5,223,589 | $3,312,699 | $7,944,089 |
| Selling General And Administration | $4,359,663 | $4,215,908 | $4,482,552 | $6,692,904 |
| Other Gand A | $4,359,663 | $4,215,908 | $4,482,552 | $6,692,904 |
| Other Special Charges | - | $-312,753 | $273,020 | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,292,125 | $4,118,071 | $2,522,422 | $-2,470,826 |
| Total Assets | $9,235,521 | $8,966,483 | $9,797,326 | $14,279,717 |
| Total Non Current Assets | $386,514 | $137,853 | $290,006 | $426,565 |
| Non Current Prepaid Assets | $22,777 | $22,777 | $22,777 | $22,777 |
| Current Assets | $8,849,007 | $8,828,630 | $9,507,320 | $13,853,152 |
| Other Current Assets | $894,311 | $905,269 | $866,014 | $274,209 |
| Current Deferred Assets | $18,543 | $103,847 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $7,936,153 | $7,819,514 | $8,446,158 | $13,359,615 |
| Cash And Cash Equivalents | $7,936,153 | $7,819,514 | $8,446,158 | $13,359,615 |
| Receivables | - | $0 | $195,148 | $219,328 |
| Non Current Deferred Assets | - | - | $0 | $20,206 |
| Non Current Accounts Receivable | - | - | $25,468 | $24,114 |
| Other Receivables | - | - | $195,148 | $104,198 |
| Accounts Receivable | - | - | $0 | $115,130 |
| Other Non Current Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $358,144 | $1,484,735 | $3,494,561 | $10,240,266 |
| Long Term Debt And Capital Lease Obligation | $244,121 | $0 | $1,122,796 | $233,627 |
| Current Debt And Capital Lease Obligation | $114,023 | $1,484,735 | $2,371,765 | $10,006,639 |
| Current Debt | - | $1,372,873 | $2,250,000 | $9,897,691 |
| Other Current Borrowings | - | $1,372,873 | $2,250,000 | $9,897,691 |
| Long Term Debt | - | - | $1,010,934 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,943,396 | $4,848,412 | $7,274,904 | $16,750,543 |
| Total Non Current Liabilities Net Minority Interest | $244,121 | $0 | $1,122,796 | $233,670 |
| Current Liabilities | $3,699,275 | $4,848,412 | $6,152,108 | $16,516,873 |
| Payables And Accrued Expenses | $3,097,127 | $3,027,235 | $3,529,228 | $6,173,542 |
| Payables | $1,115,497 | $667,896 | $1,111,226 | $3,865,796 |
| Accounts Payable | $1,115,497 | $667,896 | $1,111,226 | $3,865,796 |
| Equity | ||||
| Common Stock Equity | $5,292,125 | $4,118,071 | $2,522,422 | $-2,470,826 |
| Total Equity Gross Minority Interest | $5,292,125 | $4,118,071 | $2,522,422 | $-2,470,826 |
| Stockholders Equity | $5,292,125 | $4,118,071 | $2,522,422 | $-2,470,826 |
| Gains Losses Not Affecting Retained Earnings | $45,789 | $45,789 | $22,243 | $24,747 |
| Other Equity Adjustments | $45,789 | $45,789 | $22,243 | $24,747 |
| Retained Earnings | $-245,051,132 | $-233,970,752 | $-225,704,176 | $-219,563,446 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $43 |
| Other | ||||
| Ordinary Shares Number | $10,086,130 | $2,514,499 | $648,639 | $181,786 |
| Share Issued | $10,086,130 | $2,514,499 | $648,639 | $181,786 |
| Tangible Book Value | $5,292,125 | $4,118,071 | $2,522,422 | $-2,470,826 |
| Invested Capital | $5,292,125 | $5,490,944 | $5,783,356 | $7,426,865 |
| Working Capital | $5,149,732 | $3,980,218 | $3,355,212 | $-2,663,721 |
| Capital Lease Obligations | $358,144 | $111,862 | $233,627 | $342,575 |
| Total Capitalization | $5,292,125 | $4,118,071 | $3,533,356 | $-2,470,826 |
| Additional Paid In Capital | $250,287,382 | $238,040,520 | $228,203,706 | $217,064,964 |
| Capital Stock | $10,086 | $2,514 | $649 | $2,909 |
| Common Stock | $10,086 | $2,514 | $649 | $2,909 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $244,121 | $0 | $111,862 | $233,627 |
| Current Capital Lease Obligation | $114,023 | $111,862 | $121,765 | $108,948 |
| Pensionand Other Post Retirement Benefit Plans Current | $488,125 | $336,442 | $251,115 | $336,692 |
| Current Accrued Expenses | $1,981,630 | $2,359,339 | $2,418,002 | $2,307,746 |
| Net PPE | $363,737 | $115,076 | $241,761 | $359,468 |
| Gross PPE | $363,737 | $115,076 | $241,761 | $474,234 |
| Machinery Furniture Equipment | $8,772 | $6,113 | $11,927 | $133,247 |
| Buildings And Improvements | $354,965 | $108,963 | $229,834 | $340,987 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Accumulated Depreciation | - | - | $-121,320 | $-114,766 |
| Other Properties | - | - | - | $340,987 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,272,436 | $-8,403,618 | $-8,604,109 | $-12,662,094 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,266,553 | $-8,403,618 | $-8,604,109 | $-12,649,021 |
| Cash Flow From Continuing Operating Activities | $-10,266,553 | $-8,403,618 | $-8,604,109 | $-12,649,021 |
| Operating Gains Losses | - | - | $393,791 | - |
| Investing Activities | ||||
| Capital Expenditure | $-5,883 | - | - | $-13,073 |
| Investing Cash Flow | $-5,883 | $0 | $0 | $-13,073 |
| Cash Flow From Continuing Investing Activities | $-5,883 | $0 | $0 | $-13,073 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,164,943 | $5,812,959 | $11,587,279 | $79,354 |
| Financing Cash Flow | $10,389,075 | $7,762,089 | $3,663,506 | $76,821 |
| Cash Flow From Continuing Financing Activities | $10,389,075 | $7,762,089 | $3,663,506 | $76,821 |
| Net Other Financing Charges | $-708,236 | $-1,128,170 | $-927,072 | $-2,533 |
| Net Common Stock Issuance | $12,164,943 | $5,812,959 | $11,587,279 | $79,354 |
| Common Stock Issuance | $12,164,943 | $5,812,959 | $11,587,279 | $79,354 |
| Other | ||||
| Repayment Of Debt | $-1,372,873 | $-1,372,872 | $-7,000,000 | $0 |
| Interest Paid Supplemental Data | $35,044 | $227,735 | $552,058 | $857,411 |
| Income Tax Paid Supplemental Data | $122,155 | $42,162 | $20,730 | $16,043 |
| End Cash Position | $7,936,153 | $7,819,514 | $8,446,158 | $13,359,615 |
| Beginning Cash Position | $7,819,514 | $8,446,158 | $13,359,615 | $26,043,897 |
| Effect Of Exchange Rate Changes | $0 | $14,885 | $27,146 | $-99,009 |
| Changes In Cash | $116,639 | $-641,529 | $-4,940,603 | $-12,585,273 |
| Proceeds From Stock Option Exercised | $305,241 | $4,450,172 | $3,299 | $0 |
| Net Issuance Payments Of Debt | $-1,372,873 | $-1,372,872 | $-7,000,000 | $0 |
| Net Long Term Debt Issuance | $-1,372,873 | $-1,372,872 | $-7,000,000 | $0 |
| Long Term Debt Payments | $-1,372,873 | $-1,372,872 | $-7,000,000 | $0 |
| Net PPE Purchase And Sale | $-5,883 | $0 | $0 | $-13,073 |
| Purchase Of PPE | $-5,883 | $0 | $0 | $-13,073 |
| Change In Working Capital | $31,818 | $-348,409 | $-3,437,511 | $425,112 |
| Change In Other Current Liabilities | $-114,322 | $-121,765 | $-108,948 | $-111,122 |
| Change In Payables And Accrued Expense | $135,182 | $-407,286 | $-2,770,650 | $430,407 |
| Change In Accrued Expense | $151,683 | $85,327 | $-85,577 | $33,756 |
| Change In Payable | $-16,501 | $-492,613 | $-2,685,073 | $396,651 |
| Change In Account Payable | $-16,501 | $-492,613 | $-2,685,073 | $396,651 |
| Change In Prepaid Assets | $10,958 | $-39,255 | $-591,805 | $8,694 |
| Change In Receivables | $0 | $219,897 | $33,892 | $97,133 |
| Other Non Cash Items | $191,202 | $136,671 | $246,671 | $366,255 |
| Stock Based Compensation | $587,583 | $329,815 | $370,182 | $333,389 |
| Unrealized Gain Loss On Investment Securities | $0 | $-260,933 | $-43,066 | - |
| Depreciation Amortization Depletion | $3,224 | $5,814 | $6,554 | $24,562 |
| Depreciation And Amortization | $3,224 | $5,814 | $6,554 | $24,562 |
| Net Income From Continuing Operations | $-11,080,380 | $-8,266,576 | $-6,140,730 | $-13,798,339 |
| Gain Loss On Investment Securities | - | - | $-43,066 | - |
| Change In Other Working Capital | - | - | - | $33,756 |
| Changes In Account Receivables | - | - | - | $23,759 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-19